| Date | December 24, 2020 – present |
|---|---|
| Location | Mexico |
| Cause | COVID-19 pandemic in Mexico |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
By September 25, 2021, Mexico had administered a total of 97,523,789 doses (74.87 vaccine doses per 100 people), with 54,275,054 residents having received at least one dose and 43,248,659 residents fully vaccinated. [1] Mexico has purchased 310.8 million vaccines doses which covers 141.2% of its population. [2]
Wealthy Mexicans were reported to travel to the neighbouring United States for receiving their vaccinations. [3] In March, the White House announced that four million of doses of COVID-19 vaccines manufactured in the United States will be sent to Mexico. [4] [5]
In a survey conducted in March 2021, 52% of the Mexicans said that they were willing to get vaccinated against COVID-19, 20% said they were not sure and 28% said they would not get vaccinated. [6]
On 20 April 2021, President López Obrador televised himself receiving the AstraZeneca vaccine. [7] [8]
The National vaccination plan against COVID-19 has been planned as below in Mexico: [9]
Some Mexican states allowed grocery store workers, first responders, and teachers to get vaccinated around the Spring of 2021. [12]
NOT UPDATED SINCE APRIL 2021 - Mexico has contracted 79.4 million doses of the AstraZeneca/Oxford vaccine, 35 million doses of the CureVac vaccine, 22 million doses of the Johnson & Johnson vaccine, 39 million doses of the Moderna vaccine, 10 million doses of the Novavax vaccine, 34.4 million doses of the BioNTech/Pfizer vaccine, 24 million doses of the Sputnik V vaccine, 35 million doses of Convidecia, 12 million doses of the Sinopharm BIBP vaccine and 20 million doses of CoronaVac. [2] 3,305,000 doses of the AstraZeneca/Oxford vaccine have been delivered through the COVAX mechanism, [13] a global initiative that aims at equitable distribution for Covid-19 vaccines. Moreover, the United States have sent 2.5 million doses of the AstraZeneca/Oxford vaccine to Mexico. [14]
The following vaccines are authorized by the Mexican government for use against COVID-19 (approval date in parentheses): [9]
| Vaccine | Approval [15] | Deployment |
|---|---|---|
| Pfizer–BioNTech |  December 11, 2020 | December 24, 2020 |
| Oxford–AstraZeneca | January 4, 2021 | Yes |
| Convidecia | February 8, 2021 | Yes |
| Sputnik V | February 9, 2021 | Yes |
| CoronaVac | February 9, 2021 | Yes |
| Covaxin | April 6, 2021 |  Not yet |
| Janssen | May 27, 2021 | June 17, 2021 [16] |
| Moderna | August 17, 2021 | Yes |
| Sinopharm BIBP | August 27, 2021 | Yes |
| Abdala | December 28, 2021 | Not yet |
| Vaccine | Type (technology) | Phase I | Phase II | Phase III |
|---|---|---|---|---|
| Novavax | Subunit | Completed | Completed | Completed |
| GRAd-COV2 | Viral vector | Completed | Completed | In progress |
| Patria | Viral vector | Completed | Completed | In progress |
| Quivax 17.4 [17] | In progress | Not yet | Not yet | |
The Secretary of Foreign Affairs, Marcelo Ebrard, released the details of the agreement between the government of Mexico, Argentina, the pharmaceutical company AstraZeneca and the Carlos Slim Foundation to produce and distribute the vaccine developed by the University of Oxford. [18]
The strategy to distribute the vaccine in Latin America, the product manufactured in the Argentine mAbxience laboratory, will be transferred to the Mexican facilities of the Liomont laboratory, which will be in charge of completing the stabilization, manufacturing and packaging process of the vaccine. The COVID-19 vaccine from the pharmaceutical company CanSino Biologics will be packaged in Querétaro, after the company requested from COFEPRIS, authorization for its emergency use of its vaccine. [19]
The COVID-19 pandemic in Panama was a part of the worldwide pandemic of the coronavirus disease caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Panama on 9 March 2020. One of the dead was a 64-year-old male, who also had diabetes and pneumonia. Of those infected, 83 were hospitalized. The infected individuals belonged to the 29-59 age group and had each recently travelled abroad. A 13-year-old girl died of COVID-19 on 23 March 2020.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.
The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.
The COVID-19 vaccination program in Peru is the national vaccination strategy to protect the population against SARS-CoV-2 employing vaccines developed for the COVID-19 pandemic in Peru. Vaccination began on 9 February 2021, after three days of arrival of first vaccines. On a nation message, the head of state Francisco Sagasti confirmed the purchase of 38 millions of vaccines, being one million of vaccines for health personnel.
On 29 January 2021, Algeria launched a COVID-19 vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
COVID-19 vaccination in Ghana began on Monday 1 March 2021 after the country became the first recipient of the Oxford-AstraZeneca COVID-19 vaccine as part of the COVAX initiative. As of 6 June 2021, Ghana has administered 1,230,000 vaccine doses.
Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.
Vaccination in Mexico includes the use of vaccines in advancing public health. Mexico has a multi-year program for immunization of children. The immunization of children is fully covered by the government of Mexico. Mexico has an adverse events committee to monitor the adverse effects of vaccination as well as a standing technical advisory group on immunization.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
COVID-19 vaccination in Nigeria is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Vaccination began on 5 March 2021. As of 28 February 2022, 17,914,944 people have received their first dose a COVID-19 vaccine, and 8,197,832 have received their second dose.
The COVID-19 vaccination in Spain is the national vaccination strategy started on 27 December 2020 in order to vaccinate the country's population against COVID-19 within the international effort to fight the COVID-19 pandemic.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
{{cite web}}: CS1 maint: numeric names: authors list (link)